Revvity Signals, the software and informatics unit of Revvity, has introduced the Signals Clinical solution, a software-as-a-service (SaaS) platform aimed at centralising complete clinical trial data.
This end-to-end clinical data science platform is designed to expedite vital trial insights and data-driven decisions to transform the access to and analysis of trial data.
Such an approach will offer rapid and actionable insights that lead to quicker clinical decisions and an accelerated delivery of new therapeutics to the market.
The integration of Signals Clinical with enterprise-class Spotfire visual analytics is set to redefine data handling within the pharmaceutical, biotechnology, and contract research industries.
The platform provides access and insight to promote clinical development and therapeutic innovation.
By centralising all clinical development data in one location, the offering provides easier self-service access to unified clinical trial data.
This centralisation facilitates a complete overview of patient safety, treatment efficacy, and trial progress.
When used in conjunction with Spotfire, Signals Clinical simplifies the data preparation and improves the delivery of assessments, including safety, efficacy, and cross-study analysis.
This reduction in manual data handling allows organisations to concentrate on delivering vital trial insights and strengthen cross-functional partnerships.
The platform also provides tailorable workflows for managing data, clinical review monitoring of trials, and integrated partnership tools.
These characteristics help study managers to document and reference queries, improving partnerships and increasing the efficiency of clinical research teams.
Revvity Signals Software SVP and general manager Kevin Willoe said: “Signals Clinical is our answer to the industry's urgent need for a solution that not only is designed to protect patient safety but also empowers data-driven decision-making with near real-time analytics.
“By integrating this platform with advanced data visualisation tools, we're enabling our customers to navigate the complexities of clinical development with greater ease and efficiency, thereby accelerating the delivery of new drugs to patients.”
